Synthonics

Focus: Synthonics is an early-stage pharmaceutical company founded in 2022 specializing in metal-coordinated pharmaceuticals with a focus on neurology. The company is pre-revenue and operating from Blacksburg, VA with minimal disclosed operational scale.

Neurology

Profile data last refreshed 2h ago · AI intelligence enriched 1w ago

Open Jobs

About Synthonics

AI assessmentNot Hiring

No open roles listed right now. Follow Synthonics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

OZANIMOD

Pre-launch (mechanism: S1P receptor modulator for potential neurology/immunology applications)

Pre-Launch

ANDA filing suggests potential generic or authorized generic strategy; S1P mechanism historically validated in MS/UC but indication strategy unclear.

Help build intelligence for Synthonics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a 2022-founded company with a novel, differentiated platform in metal-coordinated pharmaceuticals—a largely unexplored modality in neurology.
Early-stage environment offers rare exposure to foundational drug discovery, formulation chemistry, and regulatory strategy from inception.
Potential to shape IP portfolio and scientific direction during the critical pre-clinical-to-IND transition phase.

Watch Out For

Zero disclosed funding, revenue, employee count, or hiring activity—extreme uncertainty about runway, capitalization, and survival probability.
Single Phase 1/2 trial (Chylobinoid for RLS) and two generic ANDA filings (not novel drug development) suggest limited internal pipeline maturity or commercial momentum.
Pre-revenue status with no disclosed financial backing raises serious concerns about payroll stability, equity liquidity, and career continuity.

Generated by Claude from Synthonics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LEVOCETIRIZINE DIHYDROCHLORIDE

Chronic idiopathic urticaria; allergic rhinitis (pediatric and adult)

Post-LOE

Post-LOE generic antihistamine; commodity market with minimal differentiation—likely a cash-flow or portfolio placeholder rather than strategic asset.

TAMSULOSIN HYDROCHLORIDE

Benign prostatic hyperplasia; urinary symptoms

Post-LOE

Post-LOE alpha-1 adrenergic antagonist; mature generic category with no differentiation—suggests portfolio is anchored in off-patent, low-growth assets.

Pipeline & Clinical Trials

Chylobinoid Topical Cream

Restless Legs Syndrome

Phase 1/2

Clinical Trials (1)

NCT06570941Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2022

Portfolio: 3 approved products, 1 clinical trial

Top TAs: Cardiovascular, Dermatology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Pre-Launch1 (33%)

Post-LOE2 (67%)

3 total products

Therapeutic Area Focus

Cardiovascular

1 marketed

Dermatology